


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of the formula (I):



(I)

in which

R<sup>1</sup> is selected from the group consisting of C<sub>(1-3)</sub> alkyl, C<sub>(2-3)</sub> alkenyl, C<sub>(2-3)</sub> alkynyl;

R<sup>2</sup> is halogen;

R<sup>3</sup> is selected from the group consisting of Br, optionally fluoro-substituted C<sub>(1-3)</sub> alkyl, optionally fluoro-substituted C<sub>(2-3)</sub> alkenyl, and C<sub>(2-3)</sub> alkynyl;


R<sup>4</sup> is selected from the group consisting of H, and C<sub>(1-3)</sub> alkyl;

Y is C<sub>(1-3)</sub> alkyl; and

Z is selected from the group consisting of substituted or unsubstituted heteroaryl imidazole, substituted or unsubstituted quinolone, substituted or unsubstituted benzimidazole, substituted or unsubstituted fused heteroaryl pyridone, substituted or unsubstituted fused aryl pyrimidone, or substituted or unsubstituted fused heteroaryl pyrimidone.

2. (cancelled)

3. (Original) A compound according to claim 1, wherein the compound is a compound of the formula (III):



(III)

in which:

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $Y$  are defined as in Claim 1; and

$R^6$  is selected from the group consisting of halo, cyano, hydroxy, ( $C_{1-6}$ )alkyl, optionally substituted by a member selected from the group consisting of halo, hydroxy, amino, mono to perfluoro( $C_{1-3}$ )alkyl, carboxy or ( $C_{1-6}$ )alkoxycarbonyl). ( $C_{3-7}$ )cycloalkyl,  $C_{(1-6)}$  alkoxy, amino, mono- or di- $(C_{1-6})$ alkylamino, acylamino, carboxy, ( $C_{1-6}$ )alkoxycarbonyl, carboxy( $C_{1-6}$ )alkyloxy, ( $C_{1-6}$ )alkylthio, ( $C_{1-6}$ )alkylsulphanyl, ( $C_{1-6}$ )alkylsulphonyl, sulphamoyl, mono- and di- $(C_{1-6})$ alkylsulphamoyl, carbamoyl, mono- and di- $(C_{1-6})$ alkylcarbamoyl, and heterocyclyl;

$m$  is 0 or an integer from 1 to 3.

4-5. (cancelled)

6. (currently amended) A compound according to ~~any of claims 1-5~~

in which:

$R^1$  is selected from the group consisting of methyl, allyl, propene, and propyne;

$R^2$  is Br;

$R^3$  is selected from the group consisting of Br, ethyl, cyclopropyl, difluoromethyl, trifluoromethyl, vinyl, fluorovinyl, and ethyne;

$R^4$  is H;

$Y$  is  $C_2$  alkyl; and

$Z$  is selected from the group consisting of quinoline, quinoloneheteroaryl imidazole, benzimidazole, and heteroaryl pyrimidone.

7. (currently amended) A salt of a compound according to ~~any of claim 1-6~~.

8. (Original) The salt of claim 7, wherein the salt is a pharmaceutically acceptable salt.

9. (currently amended) The compound of claim 1, wherein the compound is selected from the group consisting of *N*-(4,5-Dibromo-3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; *N*-(4-bromo-5-ethynyl-3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; *N*-(4-bromo-3-methyl-5-vinylthiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; *N*-(4-bromo-5-(1-fluorovinyl)-3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; *N*-(4-bromo-5-ethyl-3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; *N*-(4-bromo-5-cyclopropyl-3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; *N*-(4-bromo-5- difluoromethyl -3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; *N*-(4-bromo-3-methyl -5- trifluoromethyl thiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; *N*-(4-bromo-3-(1-propynyl)-5-ethyl thiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine; and *N*-(4-bromo-3-(1-propenyl)-5-ethyl thiophen-2-ylmethyl)-*N'*-(1*H*-quinolin-4-one)propane-1,3-diamine.; ~~*N*-(4-bromo-5-(1-fluorovinyl)-3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-benzimidazole)propane-1,3-diamine;~~ ~~*N*-(4-bromo-5-difluoromethyl-3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-benzimidazole)propane-1,3-diamine;~~ ~~*N*-(4-bromo-3-methyl-5-trifluoromethylthiophen-2-ylmethyl)-*N'*-(1*H*-benzimidazole)propane-1,3-diamine; and~~ ~~*N*-(4,5-Dibromo-3-methylthiophen-2-ylmethyl)-*N'*-(1*H*-thieno-[3,2-d]pyrimidin-4-one)propane-1,3-diamine.~~

10. (cancelled)

11. (currently amended) A pharmaceutical composition comprising a compound or salt of any of claim 1-91 and a pharmaceutically acceptable carrier or excipient.

12-13. (cancelled)

14. (new) A compound according to claim 3

in which:

R<sup>1</sup> is selected from the group consisting of methyl, allyl, propene, and propyne;

R<sup>2</sup> is Br;

R<sup>3</sup> is selected from the group consisting of Br, ethyl, cyclopropyl, difluoromethyl, trifluoromethyl, vinyl, fluorovinyl, and ethyne;

R<sup>4</sup> is H;

Y is C<sub>2</sub> alkyl; and

Z is quinolone.

15. (new) A pharmaceutical composition comprising a compound or salt of claim 3 and a pharmaceutically acceptable carrier or excipient.

16. (new) A salt of a compound according to claim 3.

17. (new) The salt of claim 14, wherein the salt is a pharmaceutically acceptable salt.

18. (new) A salt of a compound according to claim 1,  
in which,

R<sup>1</sup> is selected from the group consisting of methyl, allyl, propene, and propyne;

R<sup>2</sup> is Br;

R<sup>3</sup> is selected from the group consisting of Br, ethyl, cyclopropyl, difluoromethyl, trifluoromethyl, vinyl, fluorovinyl, and ethyne;

R<sup>4</sup> is H;

Y is C<sub>2</sub> alkyl; and

Z is quinolone..

19. (new) A salt of a compound according to claim 3,  
in which,

R<sup>1</sup> is selected from the group consisting of methyl, allyl, propene, and propyne;

R<sup>2</sup> is Br;

R<sup>3</sup> is selected from the group consisting of Br, ethyl, cyclopropyl, difluoromethyl, trifluoromethyl, vinyl, fluorovinyl, and ethyne;

R<sup>4</sup> is H;

Y is C<sub>2</sub> alkyl; and

Z is quinolone.

20. (new) The salt of claim 19, wherein the salt is a pharmaceutically acceptable salt.

21. (new) A method of treating a bacterial infection, comprising administering a compound of claim 1 to a patient in need thereof.

22. (new) A method of treating a bacterial infection, comprising administering a compound of claim 3 to a patient in need thereof.

23. (new) A method of treating a bacterial infection, comprising administering a compound of claim 6 to a patient in need thereof.

24. (new) A method of treating a bacterial infection, comprising administering a compound of claim 7 to a patient in need thereof.

25. (new) A method of treating a bacterial infection, comprising administering a compound of claim 8, to a patient in need thereof.

26. (new) A method of treating a bacterial infection, comprising administering a compound of claim 9 to a patient in need thereof.

27. (new) A method of treating a bacterial infection, comprising administering a compound of claim 14 to a patient in need thereof.

28. (new) A method of treating a bacterial infection, comprising administering a compound of claim 15 to a patient in need thereof.

29. (new) A method of treating a bacterial infection, comprising administering a compound of claim 16 to a patient in need thereof.

30. (new) A method of treating a bacterial infection, comprising administering a compound of claim 17 to a patient in need thereof.

31. (new) A method of treating a bacterial infection, comprising administering a compound of claim 18 to a patient in need thereof.

32. (new) A method of treating a bacterial infection, comprising administering a compound of claim 19 to a patient in need thereof.

33. (new) A method of treating a bacterial infection, comprising administering a compound of claim 20 to a patient in need thereof.